WHO Approves Second Mpox Vaccine for Emergency Use

The LC16m8 vaccine by KM Biologics is now authorized for use in children over one year, enhancing efforts to control outbreaks in Africa.

The World Health Organization has granted emergency use listing to the LC16m8 mpox vaccine, marking it the second vaccine approved for the disease.
Japan has pledged to donate 3.05 million doses of the LC16m8 vaccine to the Democratic Republic of Congo, the country hardest hit by the outbreak.
The vaccine is approved for individuals over one year old, providing a critical tool for protecting children, who are especially vulnerable to mpox.
The LC16m8 vaccine is not recommended for use during pregnancy or in immunocompromised individuals, including those with active cancer or certain HIV conditions.
The WHO continues to monitor the global situation, with over 115,000 lab-confirmed mpox cases reported worldwide since 2022, and is working to ensure vaccine availability and safety.